Muscarinic receptor
9 drugs Respiratory
4
approved indications
9
Approved Drugs
9
Companies
12
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 9 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Baxter 1 drug
Boehringer Ingelheim 1 drug
SCIEGEN PHARMS 1 drug
By Therapeutic Area
Other 8 drugs
Respiratory 1 drugs
Drugs by Company PRO
Baxter 1 drug
Boehringer Ingelheim 1 drug
SCIEGEN PHARMS 1 drug
UPJOHN 1 drug
Pfizer 1 drug
ORASIS PHARMS 1 drug
LENZ THERAP 1 drug
AbbVie 1 drug
GLENMARK PHARMS LTD 1 drug
By Therapeutic Area
Other 8 drugs
TRANSDERM SCOP, SOLIFENACIN SUCCINATE, DETROL LA, TOVIAZ +4 more
Respiratory 1 drugs
ATROVENT HFA
Indications Treated
Overactive BladderUrge Urinary IncontinencePresbyopiaNauseaVomitingMotion SicknessPost-Operative Nausea and VomitingBronchospasmChronic Obstructive Pulmonary DiseaseChronic BronchitisEmphysemaNeurogenic Detrusor Overactivity
All Drugs Targeting Muscarinic receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TRANSDERM SCOP | Baxter | 1979 | 4 | |
| ATROVENT HFA | Boehringer Ingelheim | 2004 | 4 | Respiratory |
| SOLIFENACIN SUCCINATE | SCIEGEN PHARMS | 2014 | 2 | |
| DETROL LA | UPJOHN | 2000 | 2 | |
| TOVIAZ | Pfizer | 2008 | 2 | |
| QLOSI | ORASIS PHARMS | 2023 | 1 | |
| VIZZ | LENZ THERAP | 2025 | 1 | |
| VUITY | AbbVie | 2021 | 1 | |
| TROSPIUM CHLORIDE | GLENMARK PHARMS LTD | 2010 | - |